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BACKGROUND: Prescription opioid dependence is in-
creasing, but treatment outcomes with office-based
buprenorphine/naloxone among these patients have
not been described.
METHODS: We compared demographic, clinical char-
acteristics and treatment outcomes among 200 patients
evaluated for entry into a trial of primary care office-
based buprenorphine/naloxone treatment stratifying
on those who reported exclusive heroin use (n=124),
heroin and prescription opioid use (n=47), or only
prescription opioid use (n=29).
RESULTS: Compared to heroin-only patients, prescrip-
tion-opioid-only patients were younger, had fewer years
of opioid use, and less drug treatment history. They
were also more likely to be white, earned more income,
and were less likely to have Hepatitis C antibodies.
Prescription-opioid-only patients were more likely to
complete treatment (59% vs. 30%), remained in treat-
ment longer (21.0 vs. 14.2 weeks), and had a higher
percent of opioid-negative urine samples than heroin
only patients (56.3% vs. 39.8%), all p values < .05.
Patients who used both heroin and prescription opioids
had outcomes that were intermediate between heroin-
only and prescription-opioid-only patients.
CONCLUSIONS: Individuals dependent on prescription
opioids have an improved treatment response to bupre-
norphine/naloxone maintenance in an office-based
setting compared to those who exclusively or episodi-
cally use heroin.
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INTRODUCTION
The abuse of prescription opioids has increased substantially
in the past 15 years. Few studies have examined character-
istics of prescription opioid users.
1–4 A recent study examining
characteristics of heroin-only, oxycodone-only, and heroin-
and-oxycodone users, found that oxycodone-only users were
more likely to be younger, female, white, and have lower
income than heroin-only users.
1 Although these findings sug-
gest that prescription opioid users differ from heroin users, to
our knowledge no study has compared their treatment re-
sponse to primary care office-based treatment with buprenor-
phine. Buprenorphine, a partial mu opioid agonist, that is
combined with the opioid antagonist naloxone, can be pre-
scribed by office-based physicians who have undergone the
necessary training and certification.
5–8 The purpose of this
post hoc analysis was to compare demographic, psychosocial,
and substance-use characteristics and treatment responses
to buprenorphine/naloxone among prescription-opioid-only,
heroin-only, and prescription-opioid and heroin users.
METHODS
Participants
Two hundred adults (≥18 years) seeking primary-care-based
buprenorphine treatment were referred from physicians,
methadone treatment, and word of mouth. All participants
met DSM-IV TR
9 criteria for opioid dependence. Patients
were excluded if they were dependent on alcohol (n=4),
cocaine (n=2), sedatives (n=0), or benzodiazepines (n=2), or
had a medical or psychiatric disorder that precluded partic-
ipation (n=19). Twenty-five eligible individuals did not com-
plete the intake. Thirty-four did not complete the 2-week
induction. One hundred and sixty-six participants were ran-
domized in a clinical trial evaluating counseling intensity and
medication dispensing frequency. This research was approved
by Yale University; all patients provided informed consent.
Measures
Sociodemographic, medical, psychosocial, drug use, and treat-
ment information was collected before treatment. Assessment
instruments included the Center for Epidemiological Studies
Depression Scale (CESD),
10 the Treatment Motivation Scale
(TMS),
11 and the Addiction Severity Index (ASI).
12 The ASI was
only collected for the 166 individuals who entered the trial.
To evaluate treatment outcomes, 2 measures of the percent
of weekly opioid-negative (based on standard opiate tests) and
cocaine-negative urine toxicologies were computed, with mis-
sing samples counted as positive, or evaluating only provided
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527samples. The maximum consecutive weeks of abstinence from
illicit opioids and cocaine were computed for each patient.
Treatment
We used the buprenorphine/naloxone sublingual tablet for-
mulation provided at 16 mg daily after a 2-week induction. Two
dose upgrades to 20 and 24 mg were possible. Medication was
provided for daily self-administration.
Participants were randomized to 1 of 3 psychosocial treat-
ments after the 2-week induction, Standard Medical Manage-
ment (SMM) and medication pickup once weekly, SMM and
medication pickup thrice weekly, or Enhanced Medical Man-
agement (EMM) and medication pick-up thrice weekly. SMM
involved 20-minute manual-guided addiction counseling ses-
sions provided weekly by a trained nurse: EMM sessions lasted
45 minutes. Study design and results have been published
separately.
13
Data Analysis
Univariate comparisons of prescription-opioid-only, heroin-
only, and combined-use patients were conducted using chi-
square tests and analyses of variance (ANOVAs). Variables with
skewed distributions were dichotomized (see Table 1). Reten-
tion was examined using Kaplan–Meier survival analysis.
When the overall test was significant, post hoc follow-up
comparisons were conducted using Bonferroni adjustment.
In the treatment outcome analyses treatment group assign-
ment was statistically controlled.
We conducted multinomial logistic regression to examine
group differences controlling for predictor variables.
14 We
examined 2 variable domains: Sociodemographic, medical
and psychosocial characteristics, and baseline substance-use
variables, with variable entry based on univariate p<.20.
14
Likelihood ratio tests examined individual variables, with
Bonferroni adjusted follow-ups. To examine differences in
treatment response while controlling for baseline differences,
we conducted analysis of covariance (ANCOVA) with each
Table 1. Baseline Sociodemographic, Medical, and Psychosocial Characteristics of Opioid Use Groups
Characteristic Prescription-opioid-
only users
Heroin-only users Heroin-and-prescription
opioid users
P value*
Sociodemographics
Age ≤35 years, % (n) 69 (20) 40 (49) 45 (21) .02
†
Male, % (n) 83 (24) 71 (88) 87 (41) .06
White, % (n) 97 (28) 68 (84) 87 (41) .001
†, ‡
Full-time
employment, % (n)
39 (11) 37 (44) 35 (16) .93
High School or greater, % (n) 86 (24) 75 (90) 87 (40) .16
Monthly income,
≥ $1,000, % (n)
69 (20) 42 (39) 53 (24) .04
†
Never married, % (n) 48 (14) 56 (69) 63 (30) .39
Medical characteristics
ASI medical, % > 0 (n) 28 (8) 12 (11) 16 (7) .13
HCV status, negative, % (n) 86 (24) 58 (66) 72 (33) .01
†
Pyschosocial characteristics
ASI employment,
mean (SD)
0.30 (.30) 0.41 (.30) 0.37 (.30) .23
ASI legal, > 0, % (n) 34 (10) 33 (30) 27 (12) .72
ASI family/social,
mean (SD)
0.27 (.21) 0.26 (.19) 0.31 (.22) .31
ASI psychiatric, > 0, % (n) 34 (10) 27 (25) 41 (18) .26
CESD, mean (SD) 16.3 (12.1) 16.4 (12.1) 18.7 (11.6) .54
Drug use and treatment history
Years of opioid use,
mean (SD)
4.0 (5.6) 9.4 (7.6) 7.9 (8.9) .005
†
Days of opioid use in
prior 30, mean (SD)
28.4 (4.3) 28.4 (4.7) 28.0 (4.9) .87
ASI Drug, 1> 0.30, % (n) 90 (26) 65 (60) 69 (31) .04
†
Treatment motivation scale,
mean (SD)
4.8 (0.5) 4.9 (0.4) 5.1 (0.4) .08
Drug treatment history,
> 1 prior treatment, % (n)
28 (8) 65 (59) 69 (31) .001
†,§
Use of other drugs in
prior 30 days, % (n)
Alcohol 52 (15) 47 (43) 51 (23) .84
Cocaine 28 (8) 38 (35) 40 (18) .52
Marijuana 45 (13) 25 (23) 38 (17) .08
Other 21 (6) 13 (12) 27 (12) .14
ASI Alcohol, % > 0 (n) 52 (15) 47 (43) 51 (23) .84
*Based on chi-square tests for categorical variables and one-way ANOVA for continuous measures
†Heroin-only users ≠ prescription opioid−only users.
‡Heroin-only users ≠ heroin-and-prescription-opioid users.
§Prescription-opioid-only users ≠ heroin-and-prescription-opioid users.
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nomial regressions.
RESULTS
Categorization of Opioid Use Group
In the week before treatment, 29 patients reported prescription-
opioid-only use, 124 reported heroin-use only, and 47 reported
both heroin and prescription opioid use. Data regarding opioid
used for the prior month was available for the subset of
individuals who completed the 2-week induction (n=166). The
concordance between categorizations based on past-week and
past-month use was high, with 125 of 166 (75%) categorized the
same on both, and only 3 of 29 (10%) classified as prescription-
opioid-use only in the past week reporting heroin use in the
preceding 30 days.
Among patients reporting only prescription opioid use,
sustained release oxycodone (Oxycontin, 57%) was the most
common prescription opioid reported, with oxycodone/acet-
aminophen (Percocet, 18%) and hydrocodone/acetaminophen
(Vicodin, 8%) reported less frequently. Over the 4 years of the
study the percent of prescription-opioid-only users increased
from 6% to 29% (p=.02).
Univariate Analyses
Patients who used only prescription opioids were younger and
had fewer years of opioid use and less drug treatment history,
yet reported higher ASI drug severity than heroin-only
patients (Table 1). They also earned more income, were more
likely to be white, and were less likely to have Hepatitis C
(HCV) antibodies. Additionally, combined users were more
likely to be white than heroin-only patients. Prescription-
opioid-only users also had less drug treatment history than
combined users.
Multinomial Logistic Regression Analyses
For the multinomial logistic regression examining sociodemo-
graphic and clinical characteristics, the variable set of age,
gender, race, income, HCV status, and ASI medical score
significantly differentiated among the groups (N=166, p<.001).
The set of ASI drug composite score, treatment motivation,
drug treatment history, recent marijuana use, and recent
other drug use significantly differentiated among groups (N=
166, p<.001). Race, income, years of opioid use, and drug
treatment history were the only significant individual variables
(same direction as univariate results).
Treatment Outcomes
Prescription-opioid-only patients were significantly more likely
to complete treatment than heroin-only patients (Table 2). In
addition, both prescription-only and combined-use patients
remained in treatment longer than heroin only patients.
Twenty-four percent of heroin-only patients dropped out
during induction compared to 2% of combined-use patients
and none of the prescription-opioid-only patients (p<.001).
Controlling for assigned treatment, prescription-opioid-only
patients had a higher percentage of opioid-negative urines
than heroin-only and combined-use patients, and achieved
longer durations of continuous opioid abstinence than com-
bined-use patients. In the third year of the trial, we began
routinely testing all samples for oxycodone and methadone.
The findings did not change if these results were included.
Based on multinomial regression, race, income, drug treat-
ment history, and years of opioid use were included in
ANCOVAs. Prescription-opioid-only patients still showed higher
percent of opioid-negative urines (p=.03), higher percent of
opioid negative urines of tests provided (p=.008), and more
continuousweeksofopioid abstinence(p=.04)thanheroin-only
patients. Percent of cocaine-negative urine samples with mis-
sing counted as positive (p=.20), percent of cocaine-negative
urines of tests provided (p=.22), and weeks of cocaine absti-
nence (p=.20) did not differ.
Table 2. Treatment Outcome of Opioid Use Groups
Characteristic Prescription-
opioid-only
users
Heroin-
only
users
Heroin-and-
prescription-
opioid users
P value*
Treatment outcome
Treatment
completion,
%( n)
59 (17) 30 (37) 38 (18) .01
†
Retention,
mean no.
of weeks (SD)
21.0 (6.7) 14.2 (9.5) 18.9 (6.7) .002
†, ‡
Percent
opioid-
negative
urines with
missing
counted as
positive,
mean (SD)
56.3 (33.0) 39.8 (36.2) 35.3 (30.2) .03
†,§
Percent
opioid-
negative
urines of
samples
collected,
mean (SD)
75.3 (33.1) 52.9 (39.0) 48.8 (33.9) .007
†,§
Weeks of cont.
opioid
abstinence,
mean (SD)
8.2 (6.2) 5.9 (6.6) 4.5 (4.8) .04
§
Percent
cocaine-
negative
urines with
missing
counted as
positive,
mean (SD)
55.5 (32.5) 46.5 (36.8) 45.5 (31.2) .42
Percent
cocaine-
negative
urines of
samples
collected,
mean (SD)
79.7 (32.4) 72.9 (33.6) 69.4 (31.7) .43
Weeks of cont.
cocaine
abstinence,
mean (SD)
7.4 (7.6) 8.7 (6.8) 6.8 (6.0) .55
*Based on logistic regression for categorical variables and one-way
ANCOVAforcontinuous measurescontrolling forassigned treatment group
†Heroin-only users ≠ prescription-opioid-only users.
‡Heroin-only users ≠ heroin-and-prescription-opioid users.
§Prescription-opioid-only users ≠ heroin-and-prescription-opioid users.
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The findings from this study indicate that patients using only
prescription opioids showed better treatment response than
patients using heroin, even controlling for potential confound-
ers. Fifty-four percent of urine samples of patients with only
prescription opioid use were negative for opioids during the
trial. Prescription-opioid-only patients were more likely to
complete the 2-week induction, whereas nearly a quarter of
heroin-only patients did not. The study results do not indi-
cate, however, that heroin-dependent patients experience
poor treatment outcomes with office-based buprenorphine/
naloxone treatment as treatment outcomes were comparable
to prior studies of heroin-dependent patients in agonist
treatment.
5,6,15,16
Compared to heroin-only users, prescription-opioid-only
users were less likely to have HCV antibodies, had fewer
years of opioid use, and were less likely to have a history of
drug treatment, suggesting that patients using prescription
opioids alone are seeking treatment earlier in their disorder.
Office-based buprenorphine/naloxone treatment may be
particularly attractive for these patients because it provides
greater privacy, is similar to treatment for other medical
problems, and reduces patients’ time commitment compared
to methadone maintenance. The study findings suggest that
office-based treatment engages patients with prescription
opioid dependence in treatment earlier, which is consistent
with mainstreaming opiate agonist treatment
17 and with prior
research.
18,19
Limitations of our study should be noted. First, the ran-
domized clinical trial was not designed to examine character-
istics and treatment response differences between opioid
users; therefore, our findings are exploratory. Second, opioid
use categorization was based on only 1 week of self-reported
use. This was intended to provide information on individual’s
opioid use before treatment rather than a comprehensive
measure of lifetime use. Defining subtypes of opiate users
may require several types of converging information and
deserves further research. Third, the prescription-opioid-only
group was relatively small (n=29), which limits power to detect
group differences. The fact that differences were found sug-
gests such effects are large and in some cases clinically
significant. Fourth, the sample represents only treatment-
seeking opioid-dependent individuals at 1 clinical site and
may not generalize to other patients seeking treatment in
primary care.
The current findings suggest that type of opioid use is an
important factor in office-based buprenorphine/naloxone
treatment. Research is needed to evaluate whether prescrip-
tion-opioid-only users show better treatment response in
settings such as methadone maintenance. Despite the im-
proved outcome of prescription-opioid-only patients compared
to combined and heroin-only patients, there is still room to
optimize treatment response.
Acknowledgments: This research was supported by grants from
the National Institute on Drug Abuse (NIDA DA09803 and DA19246,
Richard S. Schottenfeld, PI). Drs. Fiellin and Sullivan were sup-
ported by the NIDA Physician Scientist Award (K12 DA00167). Dr.
Fiellin is a Robert Wood Johnson Foundation Generalist Physician
Faculty Scholar. The PIs and the first author had full access to all of
the data in the study and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Potencial Financial Conflict of Interest: Dr. Pantalon reported
being a consultant for Bristol-Myers Squibb, and Dr. Schottenfeld
reported owning stock in astra Zeneca, GlaxoSmithKline, Pfizer,
Sanofi-Synthelab, Wyeth, and Stryker Corporation. The other
authors reported no conflicts of interest.
Corresponding Author: Brent A. Moore, PhD; Department of
Psychiatry, Yale University School of Medicine, 219S CMHC-SAC
34 Park St., New Haven, Connecticut 06519, USA (e-mail: brent.
moore@ yale.edu).
REFERENCES
1. Office of Applied Studies. Results from the 2003 National Survey on Drug
Use and Health: National findings (DHHS Publication No. SMA 04-3964,
NHSDA Series H-25). Rockville, MD: Substance Abuse and Mental
Health Services Administration; 2004.
2. Potter JS, Hennessy G, Borrow JA, Greenfield SF, Weiss RD.
Substance use histories in patients seeking treatment for controlled-
release oxycodone dependence. Drug Alcohol Depend. 2004;76:213–15.
3. Simoni-Wastila L, Strickler G. Risk factors associated with problem use
of prescription drugs. Am J Public Health. 2004;94:266–8.
4. Simoni-Wastila L, Ritter G, Strickler G. Gender and other factors
associated with the nonmedical use of abusable prescription drugs.
Subst Use Misuse. 2004;39:1–23.
5. Fiellin DA, Pantalon MV, Pakes J, O’Connor PG, Chawarski M,
Schottenfeld RS. Treatment of heroin dependence with buprenorphine
in primary care. Am J Drug Alcohol Abuse. 2002;28:231–41.
6. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary
care. J Gen Intern Med. 2005;20:1038–41.
7. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to
primary care or human immunodeficiency virus clinics providing
methadone or buprenorphine for the management of opioid dependence.
Arch Intern Med. 2005;165:1769–76.
8. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implica-
tions for primary care. Arch Intern Med. 2004;164:277–88.
9. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 4th ed. Washington, DC: American Psychiatric Asso-
ciation; 1994.
10. Radloff LS. The CES-D Scale: a self-report depression scale for research
in the general population. Appl Psychol Meas. 1977;1:385–401.
11. Knight K, Halcom M, Simpson DD. TCU psychosocial functioning and
motivation scales: Manual on psychometric properties. Institute for
Behavioral Research: Texas Christian University; 1994.
12. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the
Addiction Severity Index. J Subst Abuse Treat. 1992;9:199–213.
13. Fiellin D, Pantalon MV, Chawarski M, et al. Buprenorphine mainte-
nance in primary care: a randomized controlled trial of counseling
conditions and medication dispensing. N Engl J Med. 2006;355:365–74.
14. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John
Wiley & Sons; 2000.
15. Fiellin DA, O’Connor PG, Chawarski M, Pantalon MV, Schottenfeld
RS. Office versus narcotic treatment program-based buprenorphine for
opioid dependence. Drug Alcohol Depend. 2002;66:S55–6.
16. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate
addiction with a sublingual-tablet formulation of buprenorphine and
naloxone. N Engl J Med. 2003;349:949–58.
17. Fiellin DA, O’Connor PG. New Federal initiatives to enhance the medical
treatment of opioid dependence. Ann Intern Med. 2002;137:688–92.
18. Sullivan LE, Chawarski M, O’Conner PG, Schottenfeld RS, Fiellin
DA. The practice of office-based buprenorphine treatment of opioid
dependence: is it associated with new patients entering treatment? Drug
Alcohol Depend. 2005;79:113–6.
19. McLeod CC, Kissin WB, Stanton A, Sonnefeld J. 30-day outcomes for
buprenorphine patients treated by a national sample of qualified
physicians. College on Problems of Drug Dependence. Orlando, FL; 2005.
530 Moore et al.: Prescriptions Opioids in Office-Based Buprenorphine JGIM